Editas Medicine Announces Pricing of Initial Public Offering

Editas Medicine Announces Pricing of Initial Public Offering

February 3, 2016

CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine.

Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors

Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors

January 29, 2016

Cambridge, Mass., January 28, 2016 – Editas Medicine, a leading genome editing company, today announced the appointment of John D. Mendlein, Ph.D., CEO of aTyr Pharma, to its board of directors.

"I am delighted to welcome Dr. Mendlein to our board," said Katrine Bosley, CEO, Editas Medicine. “His proven track record of building early, dynamic companies and developing new therapeutics for serious diseases will serve as a critical resource for us.”

Black Duck’s 2015 Growth Spurs Major Expansion at Burlington Headquarters

Black Duck’s 2015 Growth Spurs Major Expansion at Burlington Headquarters

January 27, 2016

Added 30% more employees worldwide during a year that saw 46% revenue growth, record new-customer acquisition and the release of security-focused solutions

Quanterix Announces Expansion into Asia Pacific

Quanterix Announces Expansion into Asia Pacific

January 27, 2016

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in the transformation to digital medicine with an ultrasensitive single molecule testing for the benefit of human health, today announced its expansion into several prominent APAC markets.

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

January 27, 2016

Quanterix is significantly expanding its APAC presence in an effort to meet growing demand for the company’s Simoa technology

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

January 27, 2016

Company to focus on pipeline of Pentarins™ as a unique and promising approach to treating solid tumor cancers

Lead drug candidate PEN-221 targeting neuroendocrine and small cell lung cancers to advance into clinical studies in 2016

Codiak BioSciences Closes $61 Million Series B Financing

Codiak BioSciences Closes $61 Million Series B Financing

January 26, 2016

- Funds increase support for world-leader in exosome biology to $92 million

- Codiak aims to harness exosome potential in multiple therapeutic and diagnostic areas  

Strong 2015 Places Joule as a Global Leader in Scalable Ultra-Low Carbon Fuel Technologies

Strong 2015 Places Joule as a Global Leader in Scalable Ultra-Low Carbon Fuel Technologies

January 21, 2016

Bedford, Mass.—Jan. 21, 2016—Joule, the pioneer of drop-in liquid fuels from recycled CO2, announced today that it has gained significant traction in the acceleration and commercialization of environmentally sustainable ultra-low carbon fuel technologies in 2015. Joule also announced the formal completion of its acquisition of Red Rock Biofuels, a leading project development company of renewable jet and diesel fuel based on waste from biomass or other sources.

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

January 14, 2016

LYON, France--(BUSINESS WIRE)--Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

January 12, 2016

CAMBRIDGE, Mass., January 12, 2016 – Syros Pharmaceuticals today announced the closing of a $40 million financing of preferred stock. New investor Deerfield Management Company led the financing, which also included participation from new investor Casdin Capital as well as existing investors Fidelity Management and Research Company, WuXi Healthcare Ventures, Polaris Partners, Redmile Group, Aisling Capital and Alexandria Venture Investments.